Letters, Testimony & Comments

Dear Dr. Sim: The following comments are provided by the Biotechnology Industry Organization (BIO). BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50...
Questions for the District of Columbia Board of Pharmacy for the drafting of SafeRx Frequently Asked Questions Document • Is there a threshold, such as a percentage of time working in the District as a “detailer”, to require...
RE: Concerns with Senate Bill 2863 Dear Governor Patrick, On behalf of the more than 1,200 members of the Biotechnology Industry Organization (BIO), I am writing to express concerns with SB 2863 "An Act to Control Cost Containment,...
Testimony of the Biotechnology Industry Organization to the Oregon Senate Environment & Land Use Committee Regarding Senate Bill 570: The Oregon Genetically Engineered Pharmaceutical and Industrial Crop Act April 8, 2005 On behalf of the...
Dear Mr. Chairman: On behalf of the Biotechnology Industry Organization (BIO), I am writing to encourage you to consider the very significant promise that embryonic stem cell research offers thousands of Ohioans. There is a provision in House...
BIO advocated for a provision in financial services reform that would ease regulatory burdens for small public biotechnology companies. The provision would permanently exempt companies with market capitalizations of $75 million or less from...
The 2009 Government-Business Forum on Small Business Capital Formation recommended a permanent exemption for small companies from Section 404(b) of Sarbanes-Oxley. Additionally, they recommended that the SEC increase the public float threshold for...
Dear Chairman Schapiro: The Biotechnology Industry Organization (BIO) thanks the Securities and Exchange Commission (SEC or Commission) for the opportunity to submit comments on a proposed rule to address whether short sale price restrictions or...
Re: Release No. 33-8982; File No. S7-27-08; Roadmap for the Potential Use of Financial Statements Prepared in Accordance with International Financial Reporting Standards by U.S. Issuers Dear Chairman Schapiro: The Biotechnology Industry...
Re: BIO submits comments to EITF 08-1   Dear Mr. Golden: On behalf of its members, the Biotechnology Industry Organization (“BIO”) is pleased to provide comments on the Emerging Issues Task Force (EITF) Issue No. 08-1, “...
  RE: BIO Comments on EITF 08-9 Dear Chairman Golden:   On behalf of its members, the Biotechnology Industry Organization (“BIO”) is pleased to provide comments on the Emerging Issues Task Force (EITF) Issue No. 08-9...
RE: Exposure Draft on Amendments to FASB Interpretation of FIN 46(R) Dear Chairman Herz: On behalf of its members, the Biotechnology Industry Organization (“BIO”) is pleased to provide comments on the FASB’s proposed...
On behalf of the Biotechnology Industry Organization (BIO), I am writing to express our strong support for $500 million for Cures Acceleration Network (CAN) Act, a new initiative at the National Industries of Health (NIH) that was authorized in...
We respectfully request that the Senate Appropriations Subcommittee of Labor, Health and Human Services, Education and Related Agencies include funding for the newly-enacted Cures Acceleration Network in the Fiscal Year (FY) 2011 Labor-HHS...
On behalf of its members, the Biotechnology Industry Organization (BIO) is pleased to provide comments on the proposed rulemaking by the National Institute of Standards and Technology (NIST) which prescribes policies and procedures for awarding...
  DEPARTMENT OF COMMERCE National Institute of Standards and Technology Docket Number: [100407180-0225-02] Technology Innovation Program (TIP) Notice of Availability of Funds; Amendment AGENCY: National Institute of Standards and...